• Je něco špatně v tomto záznamu ?

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

J. Polivka, F. Janku,

. 2014 ; 142 (2) : 164-75.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008464

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008464
003      
CZ-PrNML
005      
20150331113510.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pharmthera.2013.12.004 $2 doi
035    __
$a (PubMed)24333502
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Polivka, Jiri $u Department of Histology and Embryology and Biomedical Centre, Faculty of Medicine Plzen, Charles University Prague, Husova 3, 301 66 Plzen, Czech Republic; Department of Neurology, Faculty Hospital Plzen, Alej Svobody 80, 304 60 Plzen, Czech Republic.
245    10
$a Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway / $c J. Polivka, F. Janku,
520    9_
$a Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a lidé $7 D006801
650    12
$a cílená molekulární terapie $7 D058990
650    _2
$a nádory $x farmakoterapie $x enzymologie $x patologie $7 D009369
650    _2
$a 1-fosfatidylinositol-3-kinasa $x metabolismus $7 D058539
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a protoonkogenní proteiny c-akt $x antagonisté a inhibitory $x metabolismus $7 D051057
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a TOR serin-threoninkinasy $x antagonisté a inhibitory $x metabolismus $7 D058570
650    _2
$a inhibitory fosfoinositid-3-kinasy $7 D000081082
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Janku, Filip $u Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Electronic address: fjanku@mdanderson.org.
773    0_
$w MED00006662 $t Pharmacology & therapeutics $x 1879-016X $g Roč. 142, č. 2 (2014), s. 164-75
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24333502 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150331113739 $b ABA008
999    __
$a ok $b bmc $g 1065737 $s 891264
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 142 $c 2 $d 164-75 $i 1879-016X $m Pharmacology & therapeutics $n Pharmacol Ther $x MED00006662
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace